After two years of treatment with bimekizumab, 53.1% of patients experienced mild disease compared to none at baseline.
Amlenetug received Orphan Drug Designation (ODD) from the US FDA in April 2024, the EMA in May 2021 and SAKIGAKE designation ...
Regeneron UK Limited has announced that the Scottish Medicines Consortium (SMC) has accepted Libtayo (cemiplimab) for use on ...
AstraZeneca announced that its drug Lynparza (olaparib) has been approved for use in Scotland. The approval by the Scottish ...
The methodology, created in the bespoke gen AI-driven biotechnology lab of Cambridge Consultants, part of the Capgemini Group ...
The study shows that 94% of patients eliminated factor IX prophylaxis and maintained near-normal factor IX levels through ...
Qureight Ltd and Avalyn Pharma Inc have announced a strategic partnership in progressive pulmonary fibrosis (PPF). The ...
Ariceum Therapeutics, a private biotech company based in Berlin, has announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to its proprietary ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback